 And so we've done this, we've actually done this, and so we can suppress tumors, we can normalize existing tumors in the frog model. Now we have one paper on glioblastoma and a couple papers on breast cancer, human breast cancer with Madeline Uden, that where we're using these tools to actually normalize existing cells. Let's be clear, this is not about a new kind of chemotherapy to kill those cells. So what we're doing is we're not trying to kill them and we are not trying to repair the DNA. So in the case of the oncogenic mutations, they're still there, but the DNA isn't what drives. What drives the outcome is the physiology.